AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03164421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine in clomiphene resistant pcos women
Study NCT03164421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: L-carnitine in clomiphene resistant pcos women
Study NCT01372449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03267771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Suppositories Vaginal
Description: progesterone vaginal suppository
Study NCT03267771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone Oral Tablet
Description: oral progesterone drug
Study NCT03267771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: doppler ultrasound
Description: pulsed doppler ultrasound
Study NCT03267771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: doppler ultrasound
Description: pulsed doppler ultrasound
Study NCT02238288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminocaproic acid
Description: Crushed tablet in the dental socket
Study NCT02238288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine dental care
Description: Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
Study NCT02238288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lidocaine and epinephrine
Description: 2%
Study NCT02238288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and epinephrine
Description: 2%
Study NCT02238288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: 750 mg
Study NCT02238288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 750 mg
Study NCT02098057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten Healthy
Description: Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
Study NCT00444912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF plus plerixafor
Description: Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5\*10\^6 CD34+ cells/kg were collected.
Study NCT00444912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
Study NCT02098057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio~Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
Study NCT03548974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment group 1
Description: The ms-intakt/MOTOmed-intervention is a home-based program using the MOTOmed movement trainer: 12 week passive, motor-driven movement therapy followed by 12 weeks of intermittent active and passive training after the 3month assessment. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. Therapists aimed at eliciting a BORG Feedback of between 10 (fairly light) and 15 (hard). The exercise training was home-based and supervised via the internet.
Study NCT03548974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment group 2
Description: The subjects assigned to interventiongroup2 started with 12 weeks intermittent active and passive training followed by 12 weeks of no intervention (Wash out phase)
Study NCT00400439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib (RO4607381)
Description: 900mg po daily for 24 weeks
Study NCT00400439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: po daily for 24 weeks
Study NCT02348580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child centered teaching of life-skills
Description: The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
Study NCT02358993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methenamine hippurate
Description: A urinary antiseptic used for prevention of UTI
Study NCT02358993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: An antibiotic used for treatment and prevention of UTI
Study NCT04133350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Patient Engagement
Description: The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.
Study NCT04362306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planned Intervention
Description: Intervention with a member of the medical physics team to review the process of simulation, treatment planning, and subsequent treatment. This meeting will last approximately 15 minutes and at this time, the team member will explain that they are the primary resource for all the technical aspects related to the patient's treatment. Additionally, they will identify and address any concerns that patients or their caregivers have with radiation treatment and the patient will be shown the simulation infographic.
Study NCT04362306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No planned intervention
Description: Anxiety and patient satisfaction questionnaires will be completed prior to CT simulation.
Study NCT01822665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Liquid gelation capsules or tablets of 400 mg strength
Study NCT01822665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol fast dissolving tablets of 500 mg strength
Study NCT01822665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT01547156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention group
Study NCT01736033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 1 tablet(0.2mg) orally q.d.
Study NCT01736033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin
Description: 1 tablet(0.2mg) orally q.d.
Study NCT01736033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: 1 tablet(5mg) orally q.d.
Study NCT01736033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet(0.2mg) orally q.d.
Study NCT03328832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tranexamic acid
Description: Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule
Study NCT03328832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Floseal®
Description: Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
Study NCT03328832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
Study NCT03159910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shoulder-Café
Description: Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.
Study NCT03159910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder-Guidance
Description: Home-based shoulder exercise and written counselling.
Study NCT02025374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric levobupivacaine
Study NCT02025374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine % 0.5
Study NCT04326218 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Serum samples will be sent for centralised analyses in Nice.~On these samples, different analysis will be performed :~* anti-PLA2R1 and anti-THSD7A antibodies~* anti-PLA2R1 and anti-THSD7A epitopes~* HLA typing
Study NCT02785692 — intervention group
Intervention type: RADIATION
Intervention: Radiation
Description: preoperative Radiotherapy/ IMRT
Study NCT01630317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral line
Description: Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.
Study NCT01630317 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Central line vein
Description: Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
Study NCT01637896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB+BMS
Description: drug-eluting balloon predilation and bare metal stent implantation
Study NCT01637896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA+DES
Description: conventional balloon predilation and drug-eluting stent implantation
Study NCT02012218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Study NCT02012218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Study NCT03186625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Panax Notoginseng Granule
Description: Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months.
Study NCT03186625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Granule
Description: Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
Study NCT04067492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPH - 104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Study NCT04067492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren®
Description: Enteric-coated tablets, 25 mg and 50 mg
Study NCT02560090 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Surveys
Description: The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
Study NCT02560090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
Study NCT02560090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephonic Nurse Intervention
Description: A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
Study NCT02560090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person Community Health Worker
Description: An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
Study NCT03704038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP level
Description: Patients will have variable PEEP levels and will be monitored
Study NCT03704038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP level
Description: Patients will have variable PEEP levels and will be monitored
Study NCT04042454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk based anti-regurgitation infant formula
Description: Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
Study NCT02706119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous glargine insulin
Description: Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
Study NCT04042454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk based infant formula
Description: Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
Study NCT04180098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C-mill intervention
Description: A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.
Study NCT04180098 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: C-mill intervention
Description: A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.
Study NCT04180098 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Participants in the control group are placed on a waiting list.
Study NCT03020004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir (DNV) 100mg tablet administered orally twice daily
Study NCT03020004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100mg tablet administered orally twice daily
Study NCT03020004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: PegIFN subcutaneous injection at 180 mcg weekly
Study NCT03020004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin (RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)
Study NCT05011175 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Participants responded to questions about their exercise habits and perceived levels of intensity as well as demographic information.
Study NCT03374735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SETALUM™ Sealant
Description: SETALUM™ Sealant to be applied on the suture line
Study NCT05576324 — intervention group
Intervention type: DRUG
Intervention: Elexacaftor / Ivacaftor / Tezacaftor
Description: Elexacaftor / Ivacaftor / Tezacaftor is a triple drug therapy that modulates CFTR availability at (apical) cell membranes and increases opening probability.
Study NCT01714323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustained Care
Description: A 3-month program after hospital discharge with these 2 components: (1) Free Medication - A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider (Alere Wellbeing, Inc., previously Free \& Clear). IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.
Study NCT01714323 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Standard care consists of a handout with information about how to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
Study NCT00407602 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implant of Argus II Retinal Prosthesis
Description: epiretinal implantation of device
Study NCT03954548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CB-17-08 CADe
Description: CB-17-08 Augmented Endoscopy System with Computer Aided Detection (CADe) function
Study NCT01490216 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lisdexamfetamine
Description: 20mg q.d. to 70mg b.i.d
Study NCT05561647 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is non-interventional study.
Study NCT02706119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular insulin added to TPN bag
Description: Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
Study NCT02706119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin added to TPN bag
Description: Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
Study NCT04174859 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Treatment dose is following the description of physicians.
Study NCT01202240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasocitinib (CP-690,55) plus Ketoconazole
Description: Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge)
Study NCT04162470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3918
Description: Subcutaneous (SC) every week (QW) over the treatment period
Study NCT03541499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10\^7 colony forming units (CFU) or 10\^9 CFU.
Study NCT03541499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).